Haemophilia is a rare bleeding disorder that mostly occurs in men An expert explains why and shares ways to reduce the risk ...

Clotting proteins missing or are defective in hemophilia can directly affect the activity of cells responsible for bone ...

A 29-year-old local patient is about to undergo a life-changing treatment that could dramatically alter the course of his ...

it could reflect individual variation in the generation of traces of thrombin at the site of vessel-wall injury by mechanisms bypassing the intrinsic clotting defects of severe hemophilia A and ...

The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...

Hemophilia happens because one’s body doesn’t make enough protein (clotting factors) to help blood form clots. Clotting factors are proteins in one’s blood. They work with platelets to form ...

has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without ... pathway inhibitor to be allowed for the blood-clotting disorder, and the first to offer a once ...

The future of hemophilia care lies not only in technological advancements but also in the pursuit of health equity, ensuring ...

It is paramount to maintain a level of 100% of the replacement clotting factor for 2 weeks ... the biggest problem in patients with hemophilia. In hemophilia patients, it is very risky to perform ...

As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...